Troponin Segment to Hold North America Cardiac Marker Market Share During 2023-2031

According to our new research study on " North America Cardiac Marker Market Size and Forecast (2021-2031), Regional Share, Trend, and Growth Opportunity Analysis," the market value is projected to grow from US$ 1.17 billion in 2023 to US$ 2.86 billion by 2031. The North America cardiac marker market is further anticipated to record a CAGR of 11.8% from 2023 to 2031. The rising prevalence of cardiovascular diseases and a surge in the demand for point-of-care cardiac testing kits are the key driving factors behind the market development.

North America cardiac marker market is segmented into the US, Canada, and Mexico. The US is expected to be among the largest contributors to the cardiac marker market in North America. The US holds the largest share of the cardiac marker market in North America, owing to increasing product development and growing government support for enhancing heart treatment. In addition, the growing prevalence of heart diseases and the risk involved have led to the market growth. According to the Centers for Disease Control and Prevention, heart disease is one of the leading causes of death in the US. As per the same source, one person dies every 36 seconds because of CVD, i.e., approximately 655,000 Americans die from heart diseases each year.

In 2021, about 695,000 people died of heart disease in the US. One in five myocardial infarctions (MI) are asymptomatic, resulting in nearly 200,000 silent myocardial infarctions each year in the US. Therefore, developing new technologies that enable early noninvasive detection of myocardial damage is crucial. Companies are currently focusing on identifying cardiac biomarkers as these lead to a better understanding of the pathophysiology of CVDs. The timing of troponin test results is critical in helping physicians quickly diagnose and effectively treat patients. For instance, Elecsys Troponin T-Gen 5 STAT, a cardiac biomarker from Roche Diagnostics, provides results in 9 minutes and helps in rapid decision-making.

In March 2024, the US Food and Drug Administration (FDA) gave 510(k) clearance to a new high-sensitivity troponin assay developed for Polymedco's PATHFAST biomarker analyzer. With this approval, the test can be used in the US on Polymedco's PATHFAST analyzer with patients' whole blood and plasma samples. PATHFAST High Sensitivity Troponin-I results can also be used with other diagnostic information such as electrocardiogram, clinical findings, and patient symptoms to aid in diagnosing myocardial infarction.

Furthermore, the country has several hospitals and super specialty hospitals that offer diagnostic and treatment services for CVDs. The healthcare centers in the country offer facilities that are incorporated with artificial intelligence and other hi-tech technologies. Therefore, the aforementioned initiatives are anticipated to propel the growth of the market in the US during the forecast period.

Based on product type, the North America cardiac marker market is segmented into reagents and kits, and analyzers. The analyzers segment held the largest market share in 2023.

By biomarker type, the market is segmented into troponin, creatine kinase-MB, myoglobin, B-type natriuretic peptide, and others. The troponin segment held the largest share of the market in 2023.

In terms of indication, the market is segmented into congestive heart failure, myocardial infraction, acute coronary syndrome, and others. The blood sample segment held the largest market share in 2023.

In terms of end user, the market is segmented into hospitals, diagnostic laboratories, point-of-care testing facilities, and others. The hospitals segment held the largest market share in 2023.

Abbott Laboratories, F.Hoffmann-La Roche, Thermo Fischer Scientific Inc, Beckman Coulter Inc, Bio-Rad Laboratories Inc, Creative Diagnostics, Diazyme Laboratories Inc, Biomerieux SA, Hytest Ltd, and QuidelOrtho Corp are a few key companies profiled in the North America cardiac marker market report.

Companies operating in the North America cardiac marker market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the North America cardiac marker market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall North America cardiac marker market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

• In March 2024, Hytest Ltd expanded into North America with a subsidiary, Hytest North America. The company will launch local operations to better serve customers and meet growing demands. With a local team in the US, the company will strive to enhance accessibility to products and services, ensuring a smoother experience for valued customers in North America.
  
  
• In October 2023, Hytest Ltd launched latest troponin product, the recombinant chimeric human Cardiac Troponin binary Complex (Cat. # 8IFC20). This unique complex features the most stable part of cTnI (fragment 28-110) linked with TnC by a 20-aar flexible linker of the cTn I - C complex.
  
  
• In January 2023, HyTest offers 3 new clones for NT-proBNP epitopes 27-31 (MAb NT13) and 43-46 (MAbs NT45 and NT46). These new clones are working with a variety of our existing NT-proBNP antibodies in fluorescence, chemiluminescence, and lateral flow platforms. In addition, they have a very good correlation with existing commercially available proBNP assays.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com